课题基金 / 基金详情

Analgesia in Herpes Zoster and Postherpetic Neuralgia

Analgesia in Herpes Zoster and Postherpetic Neuralgia
带状疱疹和带状疱疹后神经痛的镇痛
批准号:
6384131
负责人:
Robert H Dworkin
金额:
$23.93万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2001
资助国家:
美国
项目状态:
已结题
起止时间:
2001-09-01 至 2004-08-31

项目摘要

项目成果

Robert H Dworkin的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Herpes zoster is a common and painful neurological disease that is caused by reactivation of the varicella-zoster virus. Herpes zoster pain that persists after healing of the acute infection is termed postherpetic neuralgia (PHN), a chronic pain syndrome that is often refractory to all treatment. The prevalence of PHN is expected to increase substantially in the coming decades because the incidence of herpes zoster and the risk of PHN will both increase as the population ages. Although research to improve treatment is continuing, as many as half of all patients do not currently obtain relief. For this reason, the development of interventions that prevent PHN would lead to major reductions in disability, distress, and use of health care resources. On the basis of the results of research on risk factors for PHN and its pathophysiologic mechanisms, it can be hypothesized that combined antiviral and analgesic treatment begun as soon as possible after the -onset of herpes zoster will reduce the risk of PHN. The specific aim of this planning grant is to develop the protocol and procedures for a clinical trial to test this hypothesis. The proposed trial will have the following major objectives: The primary aim will be to test the hypothesis that the risk of PHN is reduced by half in herpes zoster patients treated with an antiviral agent and an opioid analgesic compared with patients treated with the antiviral agent and matching placebo. Support for this hypothesis would have a major impact on the treatment of patients with herpes zoster and lead to a substantial reduction in the prevalence of PHN. A second major aim that will be accomplished by the proposed trial is determining whether the initiation of central mechanisms of chronic neuropathic pain can be prevented by attenuating acute pain. The answer to this question will provide important information about mechanisms of prolonged pain and have major implications for its prevention.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Analgesic, Anesthetic and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks and Pediatric Anesthesia Safety Initiative (ACTTION/PASI) (U01)
  • 批准号:
    10708076
  • 项目类别:
  • 资助金额:
    $20.0万
  • 财政年份:
    2022
  • 负责人:
    Robert H Dworkin
  • 依托单位:
Analgesic, Anesthetic and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks and Pediatric Anesthesia Safety Initiative (ACTTION/PASI) (U01)
  • 批准号:
    10607632
  • 项目类别:
  • 资助金额:
    $80.0万
  • 财政年份:
    2022
  • 负责人:
    Robert H Dworkin
  • 依托单位:
Clinical Coordinating Center for the Health Initiative in Early Phase Pain Investigation Clinical Network
  • 批准号:
    10025190
  • 项目类别:
  • 资助金额:
    $201.27万
  • 财政年份:
    2019
  • 负责人:
    Robert H Dworkin
  • 依托单位:
Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION) Public-Private Partnership
  • 批准号:
    9297674
  • 项目类别:
  • 资助金额:
    $50.0万
  • 财政年份:
    2016
  • 负责人:
    Robert H Dworkin
  • 依托单位:
海外基金